Improving Sleep Quality in ICU Patients (EARS)

November 14, 2014 updated by: Assistance Publique - Hôpitaux de Paris

Benefit of an Individual Protection Against Noise and Light on Sleep Quality in ICU Patients

Sleep architecture is deeply altered in intensive care unit (ICU patients). Among factors involved in poor sleep quality are environmental factors, such as light and noise, which are an unavoidable consequence of cares.

The aim of the study is to evaluate the benefit of earplug and sleep mask on sleep architecture and quality in ICU patients.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

It is well demonstrated that sleep architecture is deeply altered in intensive care unit (ICU patients). The consequences of this alteration are multiple: neuropsychological complication such as delirium, long-term sequels such as post-traumatic stress disorders, alteration of the circadian fluctuation of various hormones with well demonstrated deleterious impact, alteration of the immune response that may promote nosocomial infections and, finally, a decrease of respiratory muscle endurance that may compromise weaning from mechanical ventilation.

Various mechanisms contribute to sleep alteration in ICU patients, including intrinsic factors linked to disease severity, factors related to therapies such as mechanical ventilation and sedation, and environmental factors. Among environmental factors, light and noise are an unavoidable consequence of cares that strongly contribute to sleep alteration in ICU patients. It is of notice that few studies have focused on strategies to protect ICU patients against noise and light such as the systematic use of earplug and sleep mask. Although the benefit of earplug and sleep mask on sleep quality has been demonstrated in healthy subjects submitted to an environment similar to ICU, it has never been evaluated in ICU patients.

The aim of the study is to evaluate the benefit of earplug and sleep mask (designated as "protective strategy) on sleep architecture and quality in ICU patients.

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75013
        • Intensive Care Unit and Respiratory division ; Groupe hospitalier Pitie-Salpetriere and Universite Pierre et Marie Curie Paris 6

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria :

  • Admission in the ICU with expected duration of stay > 48hrs.
  • Level of sedation < 4 on Ramsay scale.
  • Interruption of sedation > 12 hrs
  • Analgesia with a maximal dose of morphine < 0.01 mg/Kg/h
  • Vasopressive therapy not exceeding 0.3 mg/Kg/min for epinephrine and 10 mg/Kg/min for dopamine.
  • Informed consent by patients or next of kind.

Exclusion criteria :

  • Known sleep disorder (apnea syndrome, narcolepsy, restless leg syndrome).
  • Central nervous disease that might impact sleep architecture or the interpretation of EEG recordings.
  • Severe liver encephalopathy (stage 3 or 4)
  • Ongoing sepsis
  • Pregnancy.
  • Age < 18 yrs.
  • No health insurance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control
Experimental: earplug and sleep mask
Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of sleep stage 3 and 4 (polysomnography)
Time Frame: day 2
Significant change of the duration of sleep stage 3 and 4 (polysomnography) in the "protective strategy group" (earplug and sleep mask) as compared to the control group (conventional strategy).
day 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nocturnal awakenings (polysomnography)
Time Frame: Day 2
in the "protective strategy group" (earplug and sleep mask) compared to the control group (conventional strategy).
Day 2
Proportion of REM sleep (polysomnography)
Time Frame: Day 2
in the "protective strategy group" (earplug and sleep mask) compared to the control group (conventional strategy).
Day 2
Total sleep time (polysomnography)
Time Frame: Day 2
in the "protective strategy group" (earplug and sleep mask) compared to the control group (conventional strategy).
Day 2
Sleep time efficiency (polysomnography)
Time Frame: Day 2
in the "protective strategy group" (earplug and sleep mask) compared to the control group (conventional strategy).
Day 2
level of anxiety and depression (HAD scale)
Time Frame: At ICU discharge, an expected average of 3 weeks
participants will be followed for the duration of ICU stay, a expected average of 3 weeks. comparison between the "protective strategy group" (earplug and sleep mask) and the control group (conventional strategy).
At ICU discharge, an expected average of 3 weeks
level of anxiety and depression (HAD scale)
Time Frame: At day 90
comparison between the "protective strategy group" (earplug and sleep mask) and the control group (conventional strategy).
At day 90
Incidence of posttraumatic stress disorder syndrome
Time Frame: At ICU discharge, an expected average of 3 weeks
participants will be followed for the duration of ICU stay, a expected average of 3 weeks. comparison between the "protective strategy group" (earplug and sleep mask) and the control group (conventional strategy).
At ICU discharge, an expected average of 3 weeks
Incidence of posttraumatic stress disorder syndrome
Time Frame: At day 90
comparison between the "protective strategy group" (earplug and sleep mask) and the control group (conventional strategy).
At day 90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

November 21, 2013

First Submitted That Met QC Criteria

November 14, 2014

First Posted (Estimate)

November 17, 2014

Study Record Updates

Last Update Posted (Estimate)

November 17, 2014

Last Update Submitted That Met QC Criteria

November 14, 2014

Last Verified

November 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intensive Care Unit Patients

Clinical Trials on earplug and sleep mask

3
Subscribe